Key facts
- Notable investors include Sichuan Venture Capital, Sichuan Development Fund, Chengdu Bio-Town Investment, Chengdu Technology Groups.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Ahead Gene
- ·The full record, as it builds
Funding rounds
No funding rounds for Ahead Gene are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ahead Gene
Developer of synthetic biological technologies designed for applications in pharmaceuticals and chemical manufacturing. The company's platform focuses on the creation and application of non-natural protein functions, integrating research and development, production, and commercialization capabilities, enabling the biotechnology and chemical industries to access comprehensive solutions for the development and implementation of advanced synthetic biological products.
- Sector
- Healthcare
- HQ
- Chengdu, China
- Founded
- 2021
- Website
- aheadgene.com/
- Ownership
- Privately Held (backing)
Ahead Gene doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ahead Gene shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ahead Gene in its N-PORT filings yet. We sweep new filings monthly.